Industry
Biotechnology
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.
Loading...
Open
2.89
Mkt cap
122M
Volume
103K
High
2.92
P/E Ratio
-1.45
52-wk high
8.49
Low
2.84
Div yield
N/A
52-wk low
2.71
Portfolio Pulse from
November 07, 2024 | 12:30 pm
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 7:16 pm
Portfolio Pulse from Benzinga Newsdesk
October 23, 2024 | 10:07 am
Portfolio Pulse from Benzinga Newsdesk
October 14, 2024 | 11:06 am
Portfolio Pulse from Benzinga Insights
September 30, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
September 30, 2024 | 8:16 pm
Portfolio Pulse from Benzinga Newsdesk
September 30, 2024 | 8:06 pm
Portfolio Pulse from Benzinga Newsdesk
September 23, 2024 | 10:32 am
Portfolio Pulse from Benzinga Newsdesk
September 13, 2024 | 3:44 pm
Portfolio Pulse from Benzinga Newsdesk
September 13, 2024 | 11:05 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.